RxDoctor Payments DataLook up a doctor →

Shenika Magee

Psychiatric/Mental Health · Mendenhall, MSNPI 1639761547

Payments from drug & device makers

$13,400in general payments, 2019–2025

Across 604 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • Alkermes, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Vanda Pharmaceuticals Inc.$1K
  • AbbVie$989
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$980
  • plus $6K from 21 others

What the payments were for

  • Food & beverage$13,398100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,400 in reported general payments places this provider in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$38,795
Medicare patients
103
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl16$30,992
Paliperidone ErPaliperidone44$15,342
TrintellixVortioxetine Hydrobromide25$15,187
Aripiprazole107$10,199
Duloxetine Hcl136$6,226
Bupropion XlBupropion Hcl134$5,139
Lamotrigine ErLamotrigine13$5,052
Ziprasidone Hcl44$4,521
Trazodone Hcl232$4,243
Quetiapine Fumarate ErQuetiapine Fumarate24$3,059
Buspirone Hcl143$2,913
Quetiapine Fumarate157$2,800
Venlafaxine Hcl ErVenlafaxine Hcl78$2,501
Hydroxyzine Hcl108$2,374
Divalproex Sodium ErDivalproex Sodium27$2,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$989$30,99216 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$387$15,18725 claims
Almatica Pharma LLCSertraline Hcl$149$55065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Mendenhall

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →